- Cannabis and cannabis-derived compounds: quality considerations for clinical research : guidance for industry1
- Case study: Missouri’s efforts to protect children missing from foster care1
- Certain Medicare beneficiaries, such as urban and Hispanic beneficiaries, were more likely than others to use telehealth during the first year of the COVID-19 pandemic1
- Challenges with vaccination data hinder state and local immunization program efforts to combat COVID-191
- Characteristics of separated children in ORR’s care: June 27, 2018–November 15, 20201
- Childhood Obesity Research Demonstration: efforts to identify effective strategies for low-income children : report to Congressional requesters1
- Chronic health conditions: federal strategy needed to coordinate diet-related efforts : report to Congressional Requesters1
- Chronic rhinosinusitis with nasal polyps: developing drugs for treatment : guidance for industry1
- Cleaner health care: hospital emissions mitigation1
- Clinical decision support software: guidance for industry and Food and Drug Administration staff1
- Clinical drug interaction studies with combined oral contraceptives: guidance for industry1
- Clinical labs: studies suggest biopsy specimen misidentification and contamination errors are infrequent : report to the Ranking Member, Committee on Finance, U.S. Senate1
- Coast Guard health care: Additional actions could help ensure beneficiaries’ access : report to congressional committees1
- Coast Guard health care: improvements needed for determining staffing needs and monitoring access to care : report to congressional committees1
- Collaborative agreements in health care: complexities, uncertainties, and considerations for oversight1
- Communication and management challenges impeded HHS's response to the zero-tolerance policy1
- Comparability Protocols for postapproval changes to the chemistry, manufacturing, and controls information in an NDA, ANDA, or BLA: guidance for industry1
- Comparative effectiveness research: Patient-Centered Outcomes Research Institute and HHS continue activities and plan new efforts : report to Congressional committees1
- Competitive generic therapies: guidance for industry1
- Compliance policy regarding blood and blood component donation suitability, donor eligibility and source plasma quarantine hold requirements: guidance for industry1